Get the Stockscreener App
8.14
1.09%
-0.09
Emergent Biosolutions Inc stock is traded at $8.14, with a volume of 693.61K.
It is down -1.09% in the last 24 hours and down -8.64% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$8.23
Open:
$8.21
24h Volume:
693.61K
Relative Volume:
0.56
Market Cap:
$434.28M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.5515
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+7.39%
1M Performance:
-8.64%
6M Performance:
+32.36%
1Y Performance:
+6.68%
1-Day Range:
$7.97
$8.295
1-Week Range:
$7.45
$8.4491
52-Week Range:
$4.02
$12.73
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.14 | 425.21M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions Secures $56 Million Contract Modification - MSN
Nomura Holdings Inc. Sells 130,800 Shares of Emergent Biosolutions Inc. $EBS - MarketBeat
H.C. Wainwright reiterates Buy rating on Emergent BioSolutions stock amid $56M contract - Investing.com
Emergent Biosolutions awarded $30 million contract modification for CYFENDUS - MSN
Trexquant Investment LP Cuts Stock Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions secures $56 million U.S. government contract By Investing.com - Investing.com Australia
Emergent BioSolutions secures $56 million U.S. government contract - Investing.com
Emergent BioSolutions (EBS) Secures $56 Million Contract for ACA - GuruFocus
Emergent gets U.S. contract update for ACAM2000 smallpox & mpox vaccine - MarketScreener
$120M Total Sales: Emergent's Smallpox Vaccine ACAM2000 Scores New $56M U.S. Government Contract - Stock Titan
Emergent Biosolutions (NYSE:EBS) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Inhalational Anthrax Treatment - MSN
Is Emergent BioSolutions Inc. trending in predictive chart modelsTrade Analysis Report & Daily Volume Surge Signals - Newser
How to build a custom watchlist for Emergent BioSolutions Inc.Watch List & Daily Chart Pattern Signals - Newser
Will earnings trigger a reversal in Emergent BioSolutions Inc.2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
What’s the beta of Emergent BioSolutions Inc. stockWeekly Risk Summary & Advanced Technical Signal Analysis - خودرو بانک
Will Emergent BioSolutions Inc. face regulatory challenges2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک
OMERS ADMINISTRATION Corp Acquires 114,500 Shares of Emergent Biosolutions Inc. $EBS - MarketBeat
Is Emergent BioSolutions Inc. showing insider buyingMarket Performance Report & Verified Technical Signals - خودرو بانک
Will Emergent BioSolutions Inc. outperform the marketM&A Rumor & Daily Stock Trend Reports - Newser
Smart tools for monitoring Emergent BioSolutions Inc.’s price action2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser
Emergent BioSolutions Inc. stock retracement – recovery analysisTrade Risk Assessment & Low Volatility Stock Suggestions - Newser
Real time scanner hits for Emergent BioSolutions Inc. explained2025 Technical Patterns & Risk Controlled Swing Alerts - Newser
Backtesting results for Emergent BioSolutions Inc. trading strategies2025 Analyst Calls & Momentum Based Trading Signals - Newser
Is Emergent BioSolutions Inc. forming a bottoming basePortfolio Return Summary & Capital Protection Trade Alerts - Newser
Emergent BioSolutions at Wells Fargo Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Building trade automation scripts for Emergent BioSolutions Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - Newser
Can swing trading help recover from Emergent BioSolutions Inc. lossesMarket Performance Summary & Fast Exit and Entry Trade Guides - Newser
Emergent BioSolutions at Wells Fargo Conference: Strategic Growth Insights - Investing.com
Sector ETF performance correlation with Emergent BioSolutions Inc.Earnings Growth Report & High Accuracy Swing Trade Signals - Newser
Heatmap analysis for Emergent BioSolutions Inc. and competitorsLong Setup & Community Supported Trade Ideas - Newser
What data driven models say about Emergent BioSolutions Inc.’s futureJuly 2025 Reactions & Verified Swing Trading Watchlist - Newser
Real time breakdown of Emergent BioSolutions Inc. stock performanceWeekly Trend Recap & Capital Efficiency Focused Ideas - Newser
Is Emergent BioSolutions Inc. meeting your algorithmic filter criteriaMarket Performance Report & Advanced Technical Signal Analysis - Newser
Can Emergent BioSolutions Inc. continue delivering strong returnsBond Market & AI Optimized Trade Strategies - خودرو بانک
Charles Schwab Investment Management Inc. Has $2.84 Million Stock Holdings in Emergent Biosolutions Inc. $EBS - MarketBeat
Order flow analysis tools used on Emergent BioSolutions Inc.July 2025 Weekly Recap & Verified Momentum Stock Ideas - Newser
Tools to monitor Emergent BioSolutions Inc. recovery probabilityPortfolio Gains Summary & Growth Focused Entry Point Reports - Newser
Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Anthrax Treatment - MSN
Ranking Emergent BioSolutions Inc. among high performing stocks via toolsJuly 2025 Retail & Capital Efficiency Focused Ideas - Newser
Is Emergent BioSolutions Inc. stock bottoming outJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser
H.C. Wainwright reiterates Buy rating on Emergent BioSolutions stock with $15 target - Investing.com Canada
Does Emergent BioSolutions Inc. stock benefit from AI growth2025 Year in Review & Daily Market Momentum Tracking - خودرو بانک
Mineralys’ strategic stock sale; Gilead, Shoreline partnership ends - Endpoints News
What high frequency data says about Emergent BioSolutions Inc.July 2025 Short Interest & Weekly Chart Analysis and Guides - Newser
Can Emergent BioSolutions Inc. hit a new high this monthBear Alert & Expert Curated Trade Setups - Newser
Tools to assess Emergent BioSolutions Inc.’s risk profile2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - Newser
Emergent: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $15 - AInvest
Emergent BioSolutions (EBS) Maintains Buy Rating and Price Targe - GuruFocus
Is Emergent BioSolutions Inc. stock reversal real or fake2025 Trading Volume Trends & Safe Entry Zone Tips - Newser
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):